Nasser H Hanna1, Suzanne E Dahlberg2, Jill M Kolesar3, Charu Aggarwal4, Fred R Hirsch5, Suresh S Ramalingam6, Joan H Schiller7. 1. Indiana University Health Simon Cancer Center, Indianapolis, Indiana. 2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts. 3. School of Pharmacy, University of Wisconsin, Madison, Wisconsin. 4. Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania. 5. School of Medicine, Division of Medical Oncology, University of Colorado, Denver, Colorado. 6. Winship Cancer Institute of Emory University, Atlanta, Georgia. 7. Hematology/Oncology Division, University of Texas Southwestern Medical Center, Dallas, Texas.
Abstract
BACKGROUND: Preclinical evidence supports the clinical investigation of inhibitors to the insulin-like growth factor receptor (IGFR) and the epidermal growth factor receptor (EGFR) either alone or in combination as treatment for patients with non-small cell lung cancer (NSCLC). METHODS:Patients with chemotherapy-naïve, advanced NSCLC who had an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible. Patients were randomized to receive carboplatin intravenously at an area under the plasma drug concentration-time curve of 6.0 plus paclitaxel 200 mg/m(2) intravenously on day 1 every 3 weeks combined with either intravenous cetuximab weekly (arm A), intravenous cixutumumab every 2 weeks (arm B), or both (arm C). Patients who had nonprogessing disease after 12 weeks of therapy were permitted to continue on maintenance antibody therapy until they developed progressive disease. The primary endpoint was progression-free survival (PFS). The study design required 180 eligible patients and had 88% power to detect a 60% increase inmedian PFS for either comparison (arm A vs arm C or arm B vs arm C) using the log-rank test. RESULTS:From September 2009 to December 2010, 140 patients were accrued. The study was closed to accrual early because of an excessive number of grade 5 events reported on arms A and C. Thirteen patients died during treatment (6 patients on arm A, 2 patients on arm B, and 5 patients on arm C), including 9 within approximately 1 month of starting therapy. The estimated median PFS for arms A, B, and C were similar at 3.4 months, 4.2 months, and 4 months, respectively. CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC.
RCT Entities:
BACKGROUND: Preclinical evidence supports the clinical investigation of inhibitors to the insulin-like growth factor receptor (IGFR) and the epidermal growth factor receptor (EGFR) either alone or in combination as treatment for patients with non-small cell lung cancer (NSCLC). METHODS:Patients with chemotherapy-naïve, advanced NSCLC who had an Eastern Cooperative Oncology Group performance status of 0 or 1 were eligible. Patients were randomized to receive carboplatin intravenously at an area under the plasma drug concentration-time curve of 6.0 plus paclitaxel 200 mg/m(2) intravenously on day 1 every 3 weeks combined with either intravenous cetuximab weekly (arm A), intravenous cixutumumab every 2 weeks (arm B), or both (arm C). Patients who had nonprogessing disease after 12 weeks of therapy were permitted to continue on maintenance antibody therapy until they developed progressive disease. The primary endpoint was progression-free survival (PFS). The study design required 180 eligible patients and had 88% power to detect a 60% increase in median PFS for either comparison (arm A vs arm C or arm B vs arm C) using the log-rank test. RESULTS: From September 2009 to December 2010, 140 patients were accrued. The study was closed to accrual early because of an excessive number of grade 5 events reported on arms A and C. Thirteen patients died during treatment (6 patients on arm A, 2 patients on arm B, and 5 patients on arm C), including 9 within approximately 1 month of starting therapy. The estimated median PFS for arms A, B, and C were similar at 3.4 months, 4.2 months, and 4 months, respectively. CONCLUSIONS: On the basis of the apparent lack of efficacy and excessive premature deaths, the current results do not support the continued investigation of carboplatin, paclitaxel, and cixutumumab either alone or in combination with cetuximab for patients with advanced NSCLC.
Authors: Yoon Soo Chang; Luo Wang; Diane Liu; Li Mao; Waun Ki Hong; Fadlo R Khuri; Ho-Young Lee Journal: Clin Cancer Res Date: 2002-12 Impact factor: 12.531
Authors: Stephanie J London; Jian-Min Yuan; Gregory S Travlos; Yu-Tang Gao; Ralph E Wilson; Ronald K Ross; Mimi C Yu Journal: J Natl Cancer Inst Date: 2002-05-15 Impact factor: 13.506
Authors: Liliane Goetsch; Alexandra Gonzalez; Olivier Leger; Alain Beck; Petrus J Pauwels; Jean François Haeuw; Nathalie Corvaia Journal: Int J Cancer Date: 2005-01-10 Impact factor: 7.396
Authors: Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler Journal: J Clin Oncol Date: 2013-07-01 Impact factor: 44.544
Authors: Douglas Burtrum; Zhenping Zhu; Dan Lu; Donna Marie Anderson; Marie Prewett; Daniel S Pereira; Rajiv Bassi; Rashed Abdullah; Andrea T Hooper; Henry Koo; Xenia Jimenez; Danielle Johnson; Robin Apblett; Paul Kussie; Peter Bohlen; Larry Witte; Daniel J Hicklin; Dale L Ludwig Journal: Cancer Res Date: 2003-12-15 Impact factor: 12.701
Authors: Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Michael V Di Maria; Robert Veve; Roy M Bremmes; Anna E Barón; Chan Zeng; Wilbur A Franklin Journal: J Clin Oncol Date: 2003-09-02 Impact factor: 44.544
Authors: A Argiris; J W Lee; J Stevenson; M G Sulecki; V Hugec; N W Choong; J N Saltzman; W Song; R M Hansen; T L Evans; S S Ramalingam; J H Schiller Journal: Ann Oncol Date: 2017-12-01 Impact factor: 32.976